vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Arcadia Biosciences, Inc. (RKDA). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $901.0K, roughly 2.0× Arcadia Biosciences, Inc.). Arcadia Biosciences, Inc. runs the higher net margin — -148.3% vs -150.5%, a 2.2% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -25.8%). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs -4.5%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Arcadia Biosciences is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.

IVF vs RKDA — Head-to-Head

Bigger by revenue
IVF
IVF
2.0× larger
IVF
$1.8M
$901.0K
RKDA
Growing faster (revenue YoY)
IVF
IVF
+48.4% gap
IVF
22.6%
-25.8%
RKDA
Higher net margin
RKDA
RKDA
2.2% more per $
RKDA
-148.3%
-150.5%
IVF
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
-4.5%
RKDA

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
RKDA
RKDA
Revenue
$1.8M
$901.0K
Net Profit
$-2.6M
$-1.3M
Gross Margin
21.4%
Operating Margin
-93.1%
-152.8%
Net Margin
-150.5%
-148.3%
Revenue YoY
22.6%
-25.8%
Net Profit YoY
-62.2%
67.1%
EPS (diluted)
$-0.77
$-0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
RKDA
RKDA
Q4 25
$901.0K
Q3 25
$1.8M
$1.3M
Q2 25
$1.9M
$1.5M
Q1 25
$1.6M
$1.2M
Q4 24
$1.7M
$1.2M
Q3 24
$1.4M
$1.5M
Q2 24
$1.8M
$1.3M
Q1 24
$1.6M
$987.0K
Net Profit
IVF
IVF
RKDA
RKDA
Q4 25
$-1.3M
Q3 25
$-2.6M
$856.0K
Q2 25
$-5.3M
$-4.5M
Q1 25
$-17.4M
$2.6M
Q4 24
$-3.6M
$-4.1M
Q3 24
$-1.6M
$-1.6M
Q2 24
$-2.2M
$1.1M
Q1 24
$-1.6M
$-2.4M
Gross Margin
IVF
IVF
RKDA
RKDA
Q4 25
21.4%
Q3 25
32.1%
Q2 25
43.4%
Q1 25
35.2%
43.2%
Q4 24
41.4%
31.9%
Q3 24
31.0%
32.9%
Q2 24
53.1%
51.5%
Q1 24
45.3%
52.3%
Operating Margin
IVF
IVF
RKDA
RKDA
Q4 25
-152.8%
Q3 25
-93.1%
-88.5%
Q2 25
-160.4%
-34.4%
Q1 25
-1042.1%
44.2%
Q4 24
-202.0%
-187.7%
Q3 24
-90.7%
-114.5%
Q2 24
-100.9%
Q1 24
-95.7%
-160.9%
Net Margin
IVF
IVF
RKDA
RKDA
Q4 25
-148.3%
Q3 25
-150.5%
65.7%
Q2 25
-283.6%
-306.4%
Q1 25
-1060.1%
216.6%
Q4 24
-211.3%
-334.5%
Q3 24
-113.8%
-104.9%
Q2 24
-122.2%
81.2%
Q1 24
-101.3%
-245.5%
EPS (diluted)
IVF
IVF
RKDA
RKDA
Q4 25
$-0.97
Q3 25
$-0.77
$0.62
Q2 25
$-13.30
$-3.26
Q1 25
$-12.53
$1.90
Q4 24
$14.86
$-2.99
Q3 24
$-15.11
$-1.18
Q2 24
$-22.39
$0.78
Q1 24
$-7.55
$-1.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
RKDA
RKDA
Cash + ST InvestmentsLiquidity on hand
$4.6M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$4.1M
Total Assets
$18.8M
$6.5M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
RKDA
RKDA
Q4 25
$4.6M
Q3 25
$5.9M
Q2 25
$4.4M
Q1 25
$3.2M
Q4 24
$4.2M
Q3 24
$6.6M
Q2 24
$8.1M
Q1 24
$8.5M
Total Debt
IVF
IVF
RKDA
RKDA
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
RKDA
RKDA
Q4 25
$4.1M
Q3 25
$5.8M
$5.4M
Q2 25
$2.6M
$4.5M
Q1 25
$3.3M
$8.9M
Q4 24
$12.7M
$6.2M
Q3 24
$-23.3K
$10.3M
Q2 24
$1.4M
$11.7M
Q1 24
$10.2K
$10.6M
Total Assets
IVF
IVF
RKDA
RKDA
Q4 25
$6.5M
Q3 25
$18.8M
$8.6M
Q2 25
$19.3M
$7.8M
Q1 25
$31.7M
$13.0M
Q4 24
$46.4M
$13.5M
Q3 24
$17.0M
$15.2M
Q2 24
$17.8M
$17.4M
Q1 24
$17.3M
$16.0M
Debt / Equity
IVF
IVF
RKDA
RKDA
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
RKDA
RKDA
Operating Cash FlowLast quarter
$-1.8M
$-861.0K
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
RKDA
RKDA
Q4 25
$-861.0K
Q3 25
$-1.8M
$-257.0K
Q2 25
$-1.7M
$-2.0M
Q1 25
$-3.5M
$-1.6M
Q4 24
$-617.4K
$-2.2M
Q3 24
$-640.8K
$-1.8M
Q2 24
$-1.5M
$-2.5M
Q1 24
$-260.6K
$-3.2M
Free Cash Flow
IVF
IVF
RKDA
RKDA
Q4 25
Q3 25
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-696.3K
Q3 24
Q2 24
$-1.5M
$-2.5M
Q1 24
$-310.3K
$-3.2M
FCF Margin
IVF
IVF
RKDA
RKDA
Q4 25
Q3 25
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-40.6%
Q3 24
Q2 24
-82.3%
-188.3%
Q1 24
-19.7%
-326.5%
Capex Intensity
IVF
IVF
RKDA
RKDA
Q4 25
0.0%
Q3 25
0.5%
0.0%
Q2 25
0.5%
0.0%
Q1 25
0.9%
0.0%
Q4 24
4.6%
0.0%
Q3 24
0.0%
0.0%
Q2 24
3.0%
0.2%
Q1 24
3.2%
1.3%
Cash Conversion
IVF
IVF
RKDA
RKDA
Q4 25
Q3 25
-0.30×
Q2 25
Q1 25
-0.61×
Q4 24
Q3 24
Q2 24
-2.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons